Allergic Rhinitis Due to Grass Pollen
11
1
1
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 11 trials
100.0%
+13.5% vs benchmark
18%
2 trials in Phase 3/4
11%
1 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (11)
Documentation of Efficacy of Intralymphatic Allergen Immunotherapy
Intralymphatic Immunotherapy With Polvac Grass & Rye Allergen Extract
Intralymphatic Immunotherapy Enhanced by Vitamin-D, a Randomized Placebo-controlled Trial and Comparison With SLIT
Determination of Grass Pollen Allergen Concentration Inducing Rhinoconjunctivitis Symptoms in Subjects Allergic to Grass Pollen in ALYATEC Allergen Exposure Chamber
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis
The Influence of Nonspecific Immunostimulation on Changes in the Concentration of iNKT Cells
ILIT: Follow-up of Rhinitis Quality of Life
Kinetics of Nasal Cytokine Responses to Mechanical Stimulation
Efficacy of Puressentiel Protective Nasal Spray in Allergic Rhinitis
Is Intralymphatic Allergen Immunotherapy Effective and Safe?
Prospective Observational Study for Determination of Minimal Clinically Important Difference of Allergic Rhinitis Symptoms Due to Grass Pollen (Equinoxe 2)